J Bone Metab.
2022 Nov;29(4):279-279. 10.11005/jbm.2022.29.4.279.
Effect of Romosozumab on Trabecular Bone Score Compared to Anti-Resorptive Agents in Postmenopausal Women with Osteoporosis
- Affiliations
-
- 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 2Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 3Division of General Internal Medicine, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul, Korea
- 4Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
- KMID: 2536850
- DOI: http://doi.org/10.11005/jbm.2022.29.4.279
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Effect of Romosozumab on Trabecular Bone Score Compared to Anti-Resorptive Agents in Postmenopausal Women with Osteoporosis
- Romosozumab for the treatment of osteoporosis
- Effect of romosozumab in premenopausal women with severe osteoporosis and anorexia nervosa
- Romosozumab: A Novel Agent in the Management of Osteoporosis
- Risk of falls in postmenopausal women treated with romosozumab: Preliminary indices from a meta-analysis of randomized, controlled trials
